Optimal treatment plan for chronic myeloid leukemia suggested by mathematical modeling

October 20, 2016
Chronic myeloid leukemia. Credit: Paulo Mourao / Wikimedia Commons

A new treatment plan that sequentially combines several drugs for chronic myeloid leukemia (CML) has the potential to reduce patients' chance of relapse and increase their life expectancy, according to a study published in PLOS Computational Biology.

CML cells often harbor a mutation called BCR-ABL that is not found in . Standard CML treatment relies on drugs—imatinib, nilotinib, or dasatinib—that target this mutation. However, some patients do not respond to treatment, or they relapse, often due to additional mutations in their .

Theoretically, combining the targeted CML drugs could improve survival, but giving them simultaneously could result in severe side effects. Qie He and Kevin Leder of the University of Minnesota, Minneapolis, along with colleagues from the University of Minnesota and the Mayo Clinic, used mathematical modeling to determine the best way to give these drugs one after the other.

The researchers combined previously established mathematical models to predict how CML cells with different mutations would respond to imatinib, nilotinib, or dasatinib. They then analysed different treatment schedules to determine combination strategies that would maximize time until disease progression for hypothetical patients.

The analysis suggests that, under a wide range of scenarios, an optimal combination schedule may be more effective at controlling CML than any of the three drugs alone. These findings will require experimental validation before they can be used to inform clinical decisions. Nonetheless, they could help pave the way to CML treatment that is customized according to the distinct characteristics of a patient's cancer cells.

"We have discovered that designing optimal anti-cancer therapies based on cellular parameters can lead to significant improvement in patient survival," says senior author Kevin Leder. "This has the potential to help in the search for personalized medicine."

Explore further: Tyrosine kinase inhibitors seem safe in CML with CKD

More information: Qie He et al, Optimized Treatment Schedules for Chronic Myeloid Leukemia, PLOS Computational Biology (2016). DOI: 10.1371/journal.pcbi.1005129

Related Stories

Tyrosine kinase inhibitors seem safe in CML with CKD

August 1, 2015
(HealthDay)—Tyrosine kinase inhibitors (TKIs) appear to be safe in patients with chronic-phase (CP) chronic myeloid leukemia (CML) and chronic kidney disease (CKD), according to a study published online July 28 in Cancer.

Combination therapy shows promise for chronic myeloid leukemia

September 7, 2016
A study in mice combining two inhibitor drugs for treatment of chronic myeloid leukemia (CML) has revealed potential for not only stopping the disease completely, but also significantly lowering the cost for treatment. CML ...

Scientists discover how to beat resistance to standard leukaemia drug

December 9, 2011
(Medical Xpress) -- Cancer Research UK-funded scientists at The Institute of Cancer Research (ICR) have revealed a technique to kill chronic myeloid leukaemia (CML) cells that have stopped responding to a targeted drug, according ...

Targeting low-oxygen patches inside lung cancer tumors could help prevent drug resistance

August 25, 2016
With the right treatment schedule, medications known as hypoxia-activated prodrugs (HAPs) could help prevent drug resistance in a subtype of lung cancer, according to a study published in PLOS Computational Biology.

Recommended for you

Researchers discover a new target for 'triple-negative' breast cancer

November 20, 2017
So-called "triple-negative" breast cancer is a particularly aggressive and difficult-to-treat form. It accounts for only about 10 percent of breast cancer cases, but is responsible for about 25 percent of breast cancer fatalities.

Clinical trial suggests new cell therapy for relapsed leukemia patients

November 20, 2017
A significant proportion of children and young adults with treatment-resistant B-cell leukemia who participated in a small study achieved remission with the help of a new form of gene therapy, according to researchers at ...

Study reveals new mechanism used by cancer cells to disarm attacking immune cells

November 20, 2017
A new study by researchers at The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute (OSUCCC - James) identifies a substance released by pancreatic cancer cells that protects ...

Cell-weighing method could help doctors choose cancer drugs

November 20, 2017
Doctors have many drugs available to treat multiple myeloma, a type of blood cancer. However, there is no way to predict, by genetic markers or other means, how a patient will respond to a particular drug. This can lead to ...

Lung cancer triggers pulmonary hypertension

November 17, 2017
Shortness of breath and respiratory distress often increase the suffering of advanced-stage lung cancer patients. These symptoms can be triggered by pulmonary hypertension, as scientists at the Max Planck Institute for Heart ...

Researchers discover an Achilles heel in a lethal leukemia

November 16, 2017
Researchers have discovered how a linkage between two proteins in acute myeloid leukemia enables cancer cells to resist chemotherapy and showed that disrupting the linkage could render the cells vulnerable to treatment. St. ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.